19 Biotech Stocks With Clinical Trial Outcomes In February

The pharma and biotech space, a defensive sector, has outperformed the broader market.

The iShares NASDAQ Biotechnology Index (ETF) IBB and the SPDR S&P Biotech (ETF) XBI have added 2.09 percent and 6.99 percent, respectively, year-to-date — versus a mere 0.3-percent gain in the S&P 500 Index. 

On Feb. 5 alone, the S&P 500 Index lost 4.1 percent.

Even as market volatility threatens to wipe out valuations, there are a few sector-specific, make-or-break events biotech investors should watch. Apart from FDA decisions, clinical trial results can also create wild swings in biotech stocks, with the directional move dependent on the market's perception of the outcomes. 

The following companies are expected to release clinical trial results in the remainder of February, with some presenting updated or fresh data at conferences while others will roll out initial data or interim analysis.

AVEO Pharmaceuticals, Inc. AVEO

  • Product Candidate: Tivozanib and Opdivo.
  • Indication: advanced renal cell carcinoma.
  • Trial: Additional data on Phase 1 trial and initial results from the Phase 2 portion.
  • Date Expected: Feb. 8–10, at the 2018 Genitourinary Cancers Symposium co-sponsored by the American Society of Clinical Oncology, or ASCO-GU. 

Catalyst Biosciences Inc CBIO

  • Product Candidate: CB2679d/ISU304.
  • Indication: Hemophilia B.
  • Trial: Phase 1/2 top-line interim data to be presented at the American Society of Hematology's 2017 annual meeting. 
  • Date Expected: Feb. 9.

Johnson & Johnson JNJ's Janssen Unit.

  • Product Candidate: Erdafitinib.
  • Indication: Bladder cancer.
  • Trial: Phase 2 data.
  • Date Expected: Feb. 9 at ASCO-GU 2018.

Rexahn Pharmaceuticals, Inc. RNN

  • Product Candidate: RX-3117.
  • Indication: Third-line treatment for advanced urothelial cancer.
  • Trial: Preliminary Phase 2a data; initial Phase 2a data presented at ASCO 2017 on June 4, 2017.
  • Date Expected: Feb. 9 at ASCO-GU 2018.

TRACON Pharmaceuticals Inc TCON

  • Product Candidate: DE-122.
  • Indication: Wet age-related macular degeneration.
  • Trial: Phase 1/2 PAVE trial.
  • Date Expected: Feb. 10 at the Angiogenesis, Exudation and Degeneration Meeting. 

Celgene Corporation CELG

  • Product Candidate: Otezla.
  • Indication: Ulcerative colitis.
  • Trial: Full Phase 2 data set.
  • Date Expected: Feb. 14-17 at the 13th Congress of the European Crohn's and Colitis Organization, or ECCO. Depending on the outcome, the company plans to initiate a Phase 3 study in 2018.

See Also: Attention Biotech Investors: February PDUFA Catalysts Come Calling

Kura Oncology Inc KURA

  • Product Candidate: Tipifarnib.
  • Indication: head and neck squamous cell carcinomas.
  • Trial: Updated Phase 2 data.
  • Date Expected: Feb. 15-17 at the Multidisciplinary Head and Neck Cancers Symposium. 

Immune Pharmaceuticals Inc IMNP

  • Product Candidate: bertilimumab.
  • Indication: moderate to severe bullous pemphigoid.
  • Trial: Positive interim Phase 2 results and Phase 2a results.
  • Date Expected: Feb. 17 — late-breaking presentations at the 2018 American Academy of Dermatology annual meeting.

Aimmune Therapeutics Inc AIMT

  • Product Candidate: AR101.
  • Indication: Peanut allergies.
  • Trial: Top-line data from a Phase 3 trial initiated in January 2017. 
  • Date Expected: No specific date scheduled.

Asterias Biotherapeutics Inc AST

  • Product Candidate: AST-OPCI.
  • Indication: Cervical spinal cord injuries. 
  • Trial: Six-month data from Cohort 3 and Cohort 4. Twelve-month data from these cohorts is expected in August; six-month top-line Phase 1/2 data is expected in June; and 12-month data in December. 
  • Date Expected: No specific date scheduled.

CorMedix Inc. CRMD

  • Product Candidate: Neutrolin. 
  • Indication: Hemodialysis Patients with Central Venous Catheters
  • Trial: LOCK-IT-100, an interim analysis of Phase 3 data
  • Date Expected: Early 2018, with a full analysis due in the second half of the year. 

Heat Biologics Inc HTBX

  • Product Candidate: Opdivo.
  • Indication: Non-small cell lung cancer.
  • Trial: Initial Phase 2 data.
  • Date Expected: Feb. 28, at Heat Biologics' analyst and investor event.

Kadmon Holdings Inc KDMN

  • Product Candidate: KD025.
  • Indication: Idiopathic pulmonary fibrosis.
  • Trial: Phase 2 data.
  • Date Expected: No specific date scheduled.

Madrigal Pharmaceuticals Inc MDGL

  • Product Candidate: MGL-3196.
  • Indication: Heterozygous familial hypercholesterolemia.
  • Trial: Phase 2 data.
  • Date Expected: Madrigal announced Thursday that MGL-3196 achieved the primary endpoint in patients with heterozygous familial hypercholesterolemia. 

Marinus Pharmaceuticals Inc MRNS

  • Product Candidate: Ganaxolone.
  • Indication: Postpartum depression.
  • Trial: Phase 2 data (Amaryllis trial).
  • Date Expected: Early 2018.

Novavax, Inc. NVAX

  • Product Candidate: NanoFlu vaccine.
  • Indication: Influenza.
  • Trial: full Phase 1/2 data (trial initiated Sept. 19, 2017).
  • Date Expected: No specific date scheduled.

RXi Pharmaceuticals Corp RXII

  • Product Candidate: RXI-109-1501.
  • Indication: Retinal scarring in advanced age-related macular degeneration.
  • Trial: Top-line Phase 1/2 data (completion of enrollment announced in June 2017).
  • Date Expected: No specific date scheduled.

Sierra Oncology Inc SRRA

  • Product Candidate: SRA737.
  • Indication: Advanced solid tumors or Non-Hodgkin's lymphoma.
  • Trial: Update on Phase 1 trials.
  • Date Expected: No specific date scheduled.

Ionis Pharmaceuticals Inc IONSRoche Holding Ltd. (ADR) RHHBY

  • Product Candidate: IONIS – HTT Rx.
  • Indication: Huntington's disease.
  • Trial: Phase 1/2 data.
  • Date Expected: The first half of 2018, most likely at the annual HD Therapeutics Conference scheduled for Feb. 26-March 1.

Related Links: 

The Alzheimer's Drug Pipeline: High Failure Rates In Research On An Increasingly Common Disease 

Pharma M&A Picks Up Momentum 

Posted In: BiotechHealth CarePreviewsTop StoriesTrading IdeasGeneral

Ad Disclosure: The rate information is obtained by Bankrate from the listed institutions. Bankrate cannot guaranty the accuracy or availability of any rates shown above. Institutions may have different rates on their own websites than those posted on Bankrate.com. The listings that appear on this page are from companies from which this website receives compensation, which may impact how, where, and in what order products appear. This table does not include all companies or all available products.

All rates are subject to change without notice and may vary depending on location. These quotes are from banks, thrifts, and credit unions, some of whom have paid for a link to their own Web site where you can find additional information. Those with a paid link are our Advertisers. Those without a paid link are listings we obtain to improve the consumer shopping experience and are not Advertisers. To receive the Bankrate.com rate from an Advertiser, please identify yourself as a Bankrate customer. Bank and thrift deposits are insured by the Federal Deposit Insurance Corp. Credit union deposits are insured by the National Credit Union Administration.

Consumer Satisfaction: Bankrate attempts to verify the accuracy and availability of its Advertisers' terms through its quality assurance process and requires Advertisers to agree to our Terms and Conditions and to adhere to our Quality Control Program. If you believe that you have received an inaccurate quote or are otherwise not satisfied with the services provided to you by the institution you choose, please click here.

Rate collection and criteria: Click here for more information on rate collection and criteria.